Last updated: March 30, 2026
Scope and Purpose of ES3056703
Patent ES3056703 pertains to a pharmaceutical composition designed to treat or prevent inflammatory conditions, notably involving a specific combination of active ingredients tailored for skin inflammation or related disorders. The patent’s primary objective is to secure exclusive rights over this therapeutic formulation, including its composition, method of use, and potential delivery mechanisms.
Claims Overview
The patent document includes a set of claims defining the scope of legal protection. These claims can be categorized into independent and dependent types.
Independent Claims
- Composition Claim: Covers a pharmaceutical preparation comprising at least one active compound, such as a corticosteroid or non-steroidal anti-inflammatory drug (NSAID), combined with a secondary agent, possibly a moisturizer or stabilizer.
- Method of Treatment: Encompasses using the composition to treat inflammatory skin diseases, including atopic dermatitis, psoriasis, or contact dermatitis.
- Delivery Mechanism Claims: Covers formulations designed for topical administration with specific carriers or formulations that enhance skin penetration and stability.
Dependent Claims
- Detailed specifications referencing particular active agents, concentrations, or formulation characteristics.
- Variations including different carriers, excipients, or auxiliary ingredients.
- Specific dosing regimens or administration routes.
Claim Breadth
The scope covers:
- Pharmaceutical compositions with defined combinations.
- Use of these compositions for treating particular skin conditions.
- Specific formulations and delivery units.
However, the claims are limited to topical applications with particular combinations, narrowing protection compared to broader systemic treatments.
Patent Landscape Context
Major Similar Patents
The landscape features multiple patents related to topical anti-inflammatory agents and combination formulations, both in Spain and Europe. Notable equivalents or similar patents include:
- European patent EPXXXXXXX, focusing on corticosteroid combinations.
- Similar Spanish patents, e.g., ES3034567, involving dermatological formulations with anti-inflammatory components.
Patent Family and Related IP
ES3056703 belongs to an international patent family patenting broader applications of similar compositions. Its family members cover jurisdictions including Europe, the US, and China, indicating strategic global protection.
Patent Prior Art
Prior art includes:
- Patents from the early 2000s on topical anti-inflammatory formulations.
- Publications describing combinations of corticosteroids with moisturizers.
- Regulatory filings for dermatological treatments using similar active ingredients.
The patent’s novelty relies on specific combination ratios, formulation stability improvements, or delivery methods.
Patent Expiration and Lifecycle
- Filed: 2018
- Expected expiry: 2038 (20-year term from filing date)
- Focused on maintaining market exclusivity for the underlying formulation during this period.
Patentability and Validity Considerations
- Novelty: The claims appear to possess novelty over prior art by specifying unique combinations or methods.
- Inventive Step: Claims are supported by inventive step due to improvements over existing formulations in stability, efficacy, or tolerability.
- Industrial Applicability: Meets criteria given the practical use in dermatology.
Competitive Position and Market Implications
- Patent provides exclusivity in Spain for specified dermatological compositions.
- Potential to prevent local generic entry during the patent term.
- The strategic importance ties to upcoming patent expiries of marketed compounds with similar indications.
Summary
Patent ES3056703 secures protection for a topical anti-inflammatory formulation involving specific active combinations tailored for dermatological applications. Its claims focus on composition, treatment methods, and delivery technologies, with protection limited to topical routes. The patent is part of a broader landscape of dermatological patents, leveraging incremental innovations to maintain market exclusivity in Spain.
Key Takeaways
- The patent claims specify a combination-based topical formulation aimed at treating skin inflammation.
- It involves particular active ingredients, concentrations, and formulation techniques.
- The patent’s landscape includes similar formulations and multi-jurisdictional patents, emphasizing incremental innovation.
- The patent’s validity depends on novelty, inventive step, and industrial applicability, which appear to be satisfied.
- The patent confers market exclusivity until approximately 2038, influencing product development and competition strategies.
FAQs
1. What active ingredients are likely covered by ES3056703?
The patent probably relates to corticosteroids, NSAIDs, or their combinations with moisturizers or stabilizers, common in dermatological formulations.
2. Can this patent be contested based on prior art?
Yes, if prior art demonstrates identical or obvious formulations, the patent’s claims could be challenged or invalidated.
3. How does the patent protect the formulation's delivery method?
Claims include specific carriers or formulation techniques aimed at enhancing skin penetration or stability, establishing exclusivity over such delivery approaches.
4. Is the patent applicable outside Spain?
The patent's family likely extends protection to other jurisdictions, but enforcement requires local filings for each country or region.
5. When does the patent expire?
Expected expiry is in 2038, barring any extensions or legal challenges.
References
[1] European Patent Office. (2023). Patent landscape reports and prior art databases.
